Obesity risk is associated with brain glucose uptake and insulin resistance.
Journal
European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
received:
08
06
2022
accepted:
26
10
2022
pubmed:
27
10
2022
medline:
3
12
2022
entrez:
26
10
2022
Statut:
epublish
Résumé
To investigate whether alterations in brain glucose uptake (BGU), insulin action in the brain-liver axis and whole-body insulin sensitivity occur in young adults in pre-obese state. Healthy males with either high risk (HR; n = 19) or low risk (LR; n = 22) for developing obesity were studied with [18F]fluoro-d-glucose ([18F]FDG)-positron emission tomography during hyperinsulinemic-euglycemic clamp. Obesity risk was assessed according to BMI, physical activity and parental overweight/obesity and type 2 diabetes. Brain, skeletal muscle, brown adipose tissue (BAT), visceral adipose tissue (VAT) and abdominal and femoral s.c. adipose tissue (SAT) glucose uptake (GU) rates were measured. Endogenous glucose production (EGP) was calculated by subtracting the exogenous glucose infusion rate from the rate of disappearance of [18F]FDG. BGU was analyzed using statistical parametric mapping, and peripheral tissue activity was determined using Carimas Software imaging processing platform. BGU was higher in the HR vs LR group and correlated inversely with whole-body insulin sensitivity (M value) in the HR group but not in the LR group. Insulin-suppressed EGP did not differ between the groups but correlated positively with BGU in the whole population, and the correlation was driven by the HR group. Skeletal muscle, BAT, VAT, abdominal and femoral SAT GU were lower in the HR group as compared to the LR group. Muscle GU correlated negatively with BGU in the HR group but not in the LR group. Increased BGU, alterations in insulin action in the brain-liver axis and decreased whole-body insulin sensitivity occur early in pre-obese state.
Identifiants
pubmed: 36288097
doi: 10.1530/EJE-22-0509
pmc: PMC9782452
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Insulin
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
917-928Références
J Nucl Med. 1986 Feb;27(2):235-8
pubmed: 3712040
J Nucl Med. 2006 Jun;47(6):1016-22
pubmed: 16741312
J Clin Endocrinol Metab. 2002 Aug;87(8):3902-10
pubmed: 12161530
Obesity (Silver Spring). 2018 Aug;26(8):1322-1331
pubmed: 29956494
Gastroenterol Clin North Am. 2010 Mar;39(1):1-7
pubmed: 20202574
J Neurosci. 2015 Mar 4;35(9):3959-65
pubmed: 25740524
Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462-8
pubmed: 15339742
Lancet. 1992 Oct 17;340(8825):925-9
pubmed: 1357346
Best Pract Res Clin Endocrinol Metab. 2005 Dec;19(4):625-35
pubmed: 16311221
Diabetes Care. 2016 Feb;39(2):292-9
pubmed: 26681717
J Clin Endocrinol Metab. 2011 Sep;96(9):E1542-9
pubmed: 21778217
Front Neuroinform. 2020 Feb 04;14:3
pubmed: 32116627
EJNMMI Res. 2015 May 14;5:32
pubmed: 26034654
J Obes. 2020 May 31;2020:6134362
pubmed: 32566274
Nat Commun. 2020 Apr 15;11(1):1841
pubmed: 32296068
J Intern Med. 2015 May;277(5):540-51
pubmed: 25041575
J Nucl Med. 1991 Jul;32(7):1432-8
pubmed: 2066802
J Pediatr. 2011 Oct;159(4):584-90
pubmed: 21514597
Nature. 2006 Dec 14;444(7121):881-7
pubmed: 17167477
J Nucl Med. 1995 Jul;36(7):1141-9
pubmed: 7790936
J Nucl Med. 1988 Feb;29(2):241-7
pubmed: 3258026
Int J Obes (Lond). 2009 Jun;33 Suppl 2:S54-8
pubmed: 19528981
Ann Med. 2008;40(7):542-52
pubmed: 18728920
Diabetes Care. 2009 Nov;32 Suppl 2:S174-7
pubmed: 19875547
J Nucl Med. 1983 Nov;24(11):987-96
pubmed: 6605418
J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90
pubmed: 4055928
J Nucl Med. 1994 Jul;35(7):1104-9
pubmed: 8014665
Gastroenterology. 2007 Feb;132(2):531-42
pubmed: 17258736
Mol Psychiatry. 2012 Jun;17(6):642-9
pubmed: 21747398
Arch Intern Med. 2005 Apr 11;165(7):777-83
pubmed: 15824297
J Clin Med. 2021 Apr 06;10(7):
pubmed: 33917464
Diabetologia. 2001 Dec;44(12):2171-9
pubmed: 11793018
Diabetes Obes Metab. 2019 Feb;21(2):218-226
pubmed: 30098134
Metabolism. 2012 Dec;61(12):1817-23
pubmed: 22748969
Diabetologia. 2000 Oct;43(10):1266-72
pubmed: 11079745
Diabetes. 2013 Aug;62(8):2747-51
pubmed: 23493575
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Int J Obes (Lond). 2022 Feb;46(2):400-407
pubmed: 34728775
Diabetes. 2011 Feb;60(2):443-7
pubmed: 21270256
J Psychopharmacol. 2012 Jan;26(1):114-24
pubmed: 21824982
Eur J Endocrinol. 2021 May 10;184(6):879-889
pubmed: 33852422
Horm Metab Res. 2018 Aug;50(8):627-639
pubmed: 30001566
Gastroenterology. 2007 Aug;133(2):496-506
pubmed: 17681171
Metabolism. 2007 Apr;56(4):533-40
pubmed: 17379013
J Nucl Med. 1999 Nov;40(11):1798-804
pubmed: 10565773
J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S57-63
pubmed: 18987271
J Clin Invest. 1992 Jun;89(6):1767-74
pubmed: 1601987
Am J Physiol Endocrinol Metab. 2000 Nov;279(5):E1122-30
pubmed: 11052968
Diabetes Obes Metab. 2020 Jul;22(7):1074-1082
pubmed: 32052537
J Nucl Med. 2001 Nov;42(11):1622-9
pubmed: 11696630
Diabetologia. 2012 Jan;55(1):175-82
pubmed: 21927893
Diabetes. 2018 Feb;67(2):334-342
pubmed: 29141982
JCI Insight. 2022 Apr 8;7(7):
pubmed: 35167495
J Nucl Med. 1989 Mar;30(3):359-66
pubmed: 2786939
Diabetes Care. 2021 Mar;44(3):788-794
pubmed: 33446523
Diabetes. 2007 Apr;56(4):1010-3
pubmed: 17287468
Metabolism. 2009 Mar;58(3):344-50
pubmed: 19217449
Mol Psychiatry. 2016 Aug;21(8):1057-62
pubmed: 26460230
J Nucl Med. 2006 Jun;47(6):945-9
pubmed: 16741303